A Phase I/II, Open Label Study of Ad-RTS-hIL-12, an Adenovirus Vector Engineered to Express hIL-12, in Combination With an Oral Activator Ligand, in Subjects With Unresectable Stage III or IV Melanoma
Phase of Trial: Phase I/II
Latest Information Update: 18 Sep 2015
At a glance
- Drugs INXN 2001 (Primary) ; Veledimex (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors ZIOPHARM Oncology
- 18 Sep 2015 According to Ziopharm media release, results presented at the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference.
- 25 Jan 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 11 Mar 2014 Planned End Date changed from 1 Jan 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History